Abstract：
Lower respiratory tract infections (LRTI) are still burdened by considerable morbidity and mortality. Rapid and appropriate treatment imply knowledge of the underlying causative pathogen; while it is tempting to offer broad spectrum antibiotics, Antimicrobial Stewardship Practices invite a judicious use of the latter, especially when bacteria are not the cause. However, the epidemiology shifts to multidrug resistant (MDR) pathogens that require optimization of molecules in order to provide optimal treatment. Novel methods requiring direct sample result testing such as the Biofire Pneumonia (PN) panel have recently been made available on the market. Syndromic testing may hence provide support in the diagnosis of LRTI. There is paucity of data concerning experiences in high MDR settings, and even less concerning the performance of these panels in pediatric settings with moderate MDR prevalence. Our study highlights the optimal sensitivity and importance of support from such methods in settings burdened by MDR presence and where fast and appropriate therapy is mandatory.
摘要：
下呼吸道感染（LRTI）仍然承受着相当大的发病率和死亡率。快速和适当的治疗意味着了解潜在的致病病原体；虽然提供广谱抗生素很诱人，抗菌药物管理实践邀请明智地使用后者，尤其是当细菌不是病因时。然而,流行病学转移到多药耐药（MDR）病原体，需要优化分子以提供最佳治疗。需要直接样品结果测试的新方法，如生物火肺炎（PN）小组最近已在市场上提供。因此，综合症测试可以为LRTI的诊断提供支持。关于高MDR设置中的经验的数据很少，更不关心这些小组在中度MDR患病率儿科环境中的表现。我们的研究强调了在存在MDR的环境中以及必须进行快速和适当治疗的情况下，此类方法支持的最佳敏感性和重要性。
